Price Paula A 4

What Happened
Paula A. Price, a director of Bristol Myers Squibb Co. (BMY), received a grant of 3,996.367 Deferred Share Units (DSUs) on 2026-02-01. The award is recorded at $55.05 per share, for a total value of $220,000. This transaction is coded as an award/grant (A) and is a derivative compensation entry rather than an open‑market purchase.

Key Details

• Transaction date: 2026-02-01; Form 4 filed: 2026-02-03 (filed within the typical 2‑business‑day window).
• Award: 3,996.367 Deferred Share Units at $55.05 per unit; aggregate value $220,000.
• Shares owned after transaction: Not specified in the information provided.
• Footnote F1: Each Deferred Share Unit converts into one share of common stock upon settlement; units become settleable when the director leaves the board or at a future date previously specified by the director.
• Footnote F2: Award is part of deferred compensation and may include dividends reinvested under the 1987 Deferred Compensation Plan for Non‑Employee Directors.
• Transaction type: A = award/grant (derivative compensation), not a market buy or sale.

Context
Deferred Share Units are a common form of director compensation that convert to actual shares at a later settlement date (often when the director leaves the board or at a preselected date). Because DSUs are not immediate open‑market purchases or sales, they generally reflect routine compensation rather than an explicit trading sentiment.